Literature DB >> 20071534

Dysregulation of mTOR signaling in fragile X syndrome.

Ali Sharma1, Charles A Hoeffer, Yukihiro Takayasu, Takahiro Miyawaki, Sean M McBride, Eric Klann, R Suzanne Zukin.   

Abstract

Fragile X syndrome, the most common form of inherited mental retardation and leading genetic cause of autism, is caused by transcriptional silencing of the Fmr1 gene. The fragile X mental retardation protein (FMRP), the gene product of Fmr1, is an RNA binding protein that negatively regulates translation in neurons. The Fmr1 knock-out mouse, a model of fragile X syndrome, exhibits cognitive deficits and exaggerated metabotropic glutamate receptor (mGluR)-dependent long-term depression at CA1 synapses. However, the molecular mechanisms that link loss of function of FMRP to aberrant synaptic plasticity remain unclear. The mammalian target of rapamycin (mTOR) signaling cascade controls initiation of cap-dependent translation and is under control of mGluRs. Here we show that mTOR phosphorylation and activity are elevated in hippocampus of juvenile Fmr1 knock-out mice by four functional readouts: (1) association of mTOR with regulatory associated protein of mTOR; (2) mTOR kinase activity; (3) phosphorylation of mTOR downstream targets S6 kinase and 4E-binding protein; and (4) formation of eukaryotic initiation factor complex 4F, a critical first step in cap-dependent translation. Consistent with this, mGluR long-term depression at CA1 synapses of FMRP-deficient mice is exaggerated and rapamycin insensitive. We further show that the p110 subunit of the upstream kinase phosphatidylinositol 3-kinase (PI3K) and its upstream activator PI3K enhancer PIKE, predicted targets of FMRP, are upregulated in knock-out mice. Elevated mTOR signaling may provide a functional link between overactivation of group I mGluRs and aberrant synaptic plasticity in the fragile X mouse, mechanisms relevant to impaired cognition in fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20071534      PMCID: PMC3665010          DOI: 10.1523/JNEUROSCI.3696-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  53 in total

Review 1.  mTOR and cancer: insights into a complex relationship.

Authors:  David M Sabatini
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

Review 2.  Transcription, translation and fragile X syndrome.

Authors:  Kathryn Garber; Karen T Smith; Danny Reines; Stephen T Warren
Journal:  Curr Opin Genet Dev       Date:  2006-05-02       Impact factor: 5.578

3.  Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.

Authors:  Elena D Nosyreva; Kimberly M Huber
Journal:  J Neurophysiol       Date:  2006-02-01       Impact factor: 2.714

4.  Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression.

Authors:  Lingfei Hou; Marcia D Antion; Daoying Hu; Corinne M Spencer; Richard Paylor; Eric Klann
Journal:  Neuron       Date:  2006-08-17       Impact factor: 17.173

Review 5.  Growing roles for the mTOR pathway.

Authors:  Dos D Sarbassov; Siraj M Ali; David M Sabatini
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

Review 6.  Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X.

Authors:  Danuta Z Loesch; Quang M Bui; Cheryl Dissanayake; Sally Clifford; Emma Gould; Danuta Bulhak-Paterson; Flora Tassone; Annette K Taylor; David Hessl; Randi Hagerman; Richard M Huggins
Journal:  Neurosci Biobehav Rev       Date:  2006-11-09       Impact factor: 8.989

7.  Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1.

Authors:  Sebastien Jacquemont; Randi J Hagerman; Paul J Hagerman; Maureen A Leehey
Journal:  Lancet Neurol       Date:  2007-01       Impact factor: 44.182

Review 8.  mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.

Authors:  Stephen G Dann; Anand Selvaraj; George Thomas
Journal:  Trends Mol Med       Date:  2007-04-23       Impact factor: 11.951

9.  Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression.

Authors:  Jessica L Banko; Lingfei Hou; Francis Poulin; Nahum Sonenberg; Eric Klann
Journal:  J Neurosci       Date:  2006-02-22       Impact factor: 6.167

Review 10.  From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome.

Authors:  Claudia Bagni; William T Greenough
Journal:  Nat Rev Neurosci       Date:  2005-05       Impact factor: 34.870

View more
  274 in total

1.  Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization.

Authors:  Hansen Wang; Susan S Kim; Min Zhuo
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

Review 2.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 3.  Local RNA translation at the synapse and in disease.

Authors:  Liqun Liu-Yesucevitz; Gary J Bassell; Aaron D Gitler; Anne C Hart; Eric Klann; Joel D Richter; Stephen T Warren; Benjamin Wolozin
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

4.  Dysregulation of mTOR signaling in neuropsychiatric disorders: therapeutic implications.

Authors:  Kirsty Sawicka; R Suzanne Zukin
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 5.  Structural plasticity upon learning: regulation and functions.

Authors:  Pico Caroni; Flavio Donato; Dominique Muller
Journal:  Nat Rev Neurosci       Date:  2012-06-20       Impact factor: 34.870

Review 6.  Mechanisms of translational regulation in synaptic plasticity.

Authors:  Wayne S Sossin; Jean-Claude Lacaille
Journal:  Curr Opin Neurobiol       Date:  2010-04-27       Impact factor: 6.627

7.  Fragile X mental retardation protein: regulator of specific mRNAs or master regulator of global translation?

Authors:  Denise Cook; Scott A Cameron; Emma V Jones
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 8.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

9.  Opposing Post-transcriptional Control of InR by FMRP and LIN-28 Adjusts Stem Cell-Based Tissue Growth.

Authors:  Arthur Luhur; Kasun Buddika; Ishara Surangi Ariyapala; Shengyao Chen; Nicholas Samuel Sokol
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

10.  Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.

Authors:  Kirsty Sawicka; Alexander Pyronneau; Miranda Chao; Michael V L Bennett; R Suzanne Zukin
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.